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 32 
ABSTRACT 33 
 34 
Background: Glioblastoma (GBM) is one of the most lethal tumor types. Hypercellular 35 
regions, named pseudopalisades, are characteristic in these tumors and have been 36 
hypothesized to be waves of migrating glioblastoma cells. These “waves” of cells are 37 
thought to be induced by oxygen and nutrient depletion caused by tumor-induced blood 38 
vessel occlusion. Although the universal presence of these structures in GBM tumors 39 
suggest that they may play an instrumental role in GBM spreading and invasion, the 40 
recreation of these structures in vitro has remained challenging. 41 
Methods: Here we present a new microfluidic model of GBM that mimics the dynamics 42 
of pseudopalisade formation. To do this, we embedded U-251 MG cells within a 43 
collagen hydrogel in a custom designed microfluidic device. By controlling the medium 44 
flow through lateral microchannels, we can mimic and control blood vessel obstruction 45 
events associated with this disease.  46 
Results: Through the use of this new system, we show that nutrient and oxygen 47 
starvation triggers a strong migratory process leading to pseudopalisade generation in 48 
vitro. These results validate the hypothesis of pseudopalisade formation and show an 49 
excellent agreement with a systems-biology model based on hypoxia-driven 50 
phenomenon.  51 
Conclusions: This paper shows the potential of microfluidic devices as advanced 52 
artificial systems capable of modeling in vivo nutrient and oxygen gradients during 53 
tumor evolution. 54 
Keywords: Glioblastoma, Microfluidics, Pseudopalisades, SU-8, Migration 55 
 56 
 57 
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 59 
INTRODUCTION 60 
 61 
Glioblastoma, also named grade IV astrocytoma, is the most common and lethal 62 
malignant primary brain tumor. Patients receiving the standard-of-care based on local 63 
radiotherapy and concomitant chemotherapy have a median survival of 14 months1. 64 
Despite the efforts of the research community, new treatments to tackle the disease 65 
are still far from the clinic. GBM tumors are highly infiltrating and fast progressing 66 
tumors2 and are characterized by two main histopathological conditions: necrotic foci 67 
typically surrounded by areas of high cellularity known as pseudopalisading regions, 68 
and microvascular proliferation2. 69 
 70 
The causes of these densely populated pesudopalisades remain poorly understood. 71 
Although the high cellularity was initially thought to be due to rapid proliferation of GBM 72 
cells, recent histological studies have shown that proliferation in pseudopalisading 73 
areas is significantly lower than in adjacent regions3. Additionally, in pseudopalisades 74 
apoptosis is substantially larger than in neighboring regions4. This evidence suggests 75 
that pseudopalisades are due to causes other than simply higher proliferation or 76 
survival rates. Recent reports have shown that in histological slices from GBM patients 77 
more than 50% of pseudopalisades clearly present a central obstructed blood vessel, 78 
and microscopic evidence of thrombosis is observed in more than 90% of samples4-6. 79 
 80 
GBM cells express several procoagulant factors which may serve to induce 81 
thrombosis7. Additional evidence shows that cells in pseudopalisades are hypoxic and 82 
overexpress HIF-1α8. Although this hypoxic microenvironment leads to microvascular 83 
hyperplasia, the associated microcirculation is very inefficient due to parenchymal 84 
edema and poor maintenance of the blood brain barrier9. As a consequence, the 85 
supply of oxygen and nutrients is compromised in the zone surrounding a thrombosis. 86 
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GBM evolution is a complex process. It has been proposed that one of the driving 87 
forces of glioma aggressiveness is nutrient and oxygen starvation3,4,10. First, GBM 88 
proliferation and secretion of pro-coagulant signals would causes thrombotic events 89 
leading to hypoxia and nutrient depletion. As a consequence, the migration of cells 90 
away from a thrombosis and towards nutrients and oxygen enriched regions could 91 
create the characteristic GBM pseudopalisades. Eventually, these migrating cells 92 
would reach other blood vessels and eventually cause the collapse of these vessels, 93 
restarting the process and creating another expanding wave of tumor cells within the 94 
brain. This hypothesis proposes that GBM cells are exposed to cyclic starvation which 95 
forces their metabolism to switch between a proliferative or migrating phenotype. 96 
 97 
Since we cannot take multiple histologic timepoints in vivo, it has not been possible to 98 
definitively observe thrombosis-induced migration in real-time and the kinetics of any 99 
such migration are not understood. This complex process is not reproducible using 100 
standard “in vitro” models because the conventional migration assays are unable to 101 
mimic the complex microenvironment described. Recently, microfabrication and 102 
microfluidic technologies have arisen, allowing the design and creation of custom high-103 
performance cell culture systems11. In this paper we describe the design, fabrication 104 
and biological validation of a microfluidic device using SU-8 technology for three-105 
dimensional GBM cell cultures under obstructed conditions. Under these conditions, 106 
nutrient starvation leads to a chemotactic process and the formation of a migratory 107 
front similar to the pseudopalisades observed in vivo and corresponding to predictive 108 
mathematical algorithms. Moreover, our results suggest that the pseudopalisading 109 
process stimulates a more aggressive behavior of GBM cells. This novel technique 110 
could help us to understand the mechanism of pseudopalisade formation and to 111 
suggest novel therapeutic targets to avoid tumor progression. These microfluidic 112 
devices represent an extremely useful platform to evaluate cellular behavior and to test 113 
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new anticancer agents in a preclinical setting that mimics the complex GBM 114 
microenvironment. 115 
 116 
METHODS 117 
 118 
Microfluidic chip fabrication 119 
Microfluidic devices were fabricated using SU-8 photolithography combined with a SU-120 
8 to SU-8 bonding process. The fabrication process was inspired by previously 121 
reported work describing the fabrication of SU-8 microdevices12,13. Briefly, several 122 
layers of SU-8 were spun onto the Kapton film and different soft bake, UV exposure 123 
and post-bake steps were performed14,15. 124 
 125 
Packaging tool fabrication  126 
In order to recreate obstructed conditions (Fig 1A), a regular flow of culture media must 127 
be provided to the microdevice through one lateral microchannel whereas the other is 128 
sealed (Fig 1B). A dedicated package was designed and fabricated to provide proper 129 
housing and hermetic connections to the microdevice inlets and outlets, allowing for 130 
automated cellular culture. Final microdevice and packaging tool are showed in Fig. 131 
1C.  132 
 133 
Cell culture 134 
C-6 cells were kindly provided by Dr Pešic (University of Belgrade) whereas U-251-MG 135 
cells were purchased from ATCC. Both cells were routinely grown in Dulbecco´s 136 
modified Eagle´s medium (DMEM) (Lonza BE12-614F) supplemented with 10% v/v 137 
fetal bovine serum (Sigma F7524) and penicillin/streptomycin (DE 17-602E) within a 138 
TEB-1000 incubator (EBERS Medical Technology). For three-dimensional cultures, all 139 
reagents, microdevices included, were placed on ice. Cells were trypsinized and 140 
resuspended in a calculated volume of medium (DMEM supplemented with 10 % fetal 141 
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bovine serum) to reach the desired concentration of cells in the final hydrogel solution. 142 
Using a chilled tip, we prepared a mixture of 24.9 µl of collagen type I 4.01 mg/ml 143 
(Corning 354236); 0.62 µl of NaOH 1N (Sigma 655104); 10 µl of DMEM 5X (Sigma 144 
D5523), 50 µl  of cell solution and 14.5 µl of sterile water. The hydrogel mixture was 145 
injected into the device using a micropipette, then a 5 µl droplet was placed on top of 146 
the central inlet to prevent hydrogel leakage and evaporation. Afterwards, the 147 
microfluidic device was placed into an incubator (37°C and 5% CO2) for 15 minutes to 148 
allow collagen polymerization. For use as a macroscopic control on viability assays, 149 
100 µl of hydrogel mixture was allowed to polymerize on Petri dishes. Medium within 150 
microdevices was refreshed once a day. Cell membrane was fluorescently labelled 151 
using vibrant Dil (Life Technologies, V-22885) following the supplier instructions. 152 
 153 
Cell Viability 154 
Stock solutions of 5 mg/ml Calcein (CAM) (Life technologies C1430) and 2 mg/ml 155 
propidium iodide (PI) (Sigma P4170) were prepared following supplier instructions. 156 
 157 
To test cell viability within microfluidic devices and in Petri dishes, stock solutions of 158 
CAM and PI were diluted to 5 and 4 µg/ml, respectively, in phosphate-buffered saline 159 
(PBS) (Lonza BE17-516F). Microdevices and petri controls were washed once with 160 
PBS, and then filled with CAM/PI. Confocal images were immediately taken using a 161 
Nikon Eclipse Ti microscope equipped with a C1 modular confocal microscope system. 162 
Images were collected at different focal planes within each microdevice and Petri 163 
control.  164 
 165 
Long-term cultures under obstructed conditions. 166 
To mimic the obstructed conditions, cells were embedded into a collagen hydrogel 167 
injected within the central microchamber of the microdevices. After 24 hours, the 168 
microdevices were loaded into the packaging tool and all inlets were sealed except for 169 
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one pair to enable medium perfusion through only one lateral microchannel (Fig. 1D). 170 
As a control group, other microdevices were left on the Petri dish and medium was 171 
manually refreshed once a day under unrestricted conditions. System evolution was 172 
followed and cell viability and distribution was evaluated at different times. Flow profile 173 
was characterized using green-fluorescent 0.2 µm diameter spheres (Life 174 
Technologies, F8811). Oxygen profile across the microchamber was measured using 175 
“Image-it Hypoxia reagent” (Life Technologies, H10498) dissolved in DMSO. Medium 176 
supplemented with 10 μM hypoxia reagent was perfused through the system for 24 177 
hours to ensure the reagent reached the microdevice. Continuous oxygen monitoring 178 
throughout all the experiment was avoided due to the reagent toxicity. Hypoxia-induced 179 
fluorescence was detected using a 488 nm laser coupled with a 650nm long-pass 180 
detector in the confocal microscope.   181 
 182 
Glucose profile analysis 183 
The presence of a glucose gradient during experiments was studied using a 184 
fluorescent glucose (2-NBDG) (Life Technologies N13195) which is imported by the 185 
cells in place of glucose. Since 2-NBDG and conventional glucose compete for the cell 186 
glucose transporters, cells were cultured within the microdevices in glucose-free 187 
DMEM (Thermos Fisher Scientific, 11966-025) supplemented with fetal calf serum, 188 
glutamine and antibiotics. This glucose-free medium was supplemented with 2-NBDG 189 
at 200 µM and perfused through one lateral microchannel. Time-lapse images were 190 
taken for 2 hours every 5 minutes to analyze NBDG penetration across the central 191 
microchamber. Long-term experiments with NBDG and absence of conventional 192 
glucose were not possible since it may affect cell behavior.   193 
 194 
Image analysis 195 
Cell analysis within the central microchamber and Petri controls was performed using 196 
automated Fiji software (http://fiji.sc/Fiji). To analyze cell distribution within the central 197 
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microchamber, only focal planes ranging from 50 μm to 250 μm were used to exclude 198 
cells attached directly to the 2D microchamber top and bottom. Selected focal planes 199 
were flipped vertically, generating the orthogonal view, which was projected to get the 200 
cell distribution across all the microchamber length. In order to analyze cell shape, cell 201 
perimeter was drawn manually and ellipse fitted-aspect ratio was calculated as the ratio 202 
between the ellipse major and minor axis. Cell directionality was also determined and 203 
plotted as a histogram referred to the medium flow direction. At least one hundred cells 204 
were analyzed in each region. 205 
 206 
Immunofluorescence 207 
Samples were fixed for 30 min with 4% paraformaldehyde (VWR J61899-AP), 208 
permeabilized using 0,1% Triton-X100 (Sigma T8787) and blocked with 5% BSA 209 
(Sigma A2058) in PBS. Samples were then incubated overnight with primary antibody 210 
(1/50 in 2,5% BSA and 0,05% Triton X-100, Santacruz anti-Ki-67 sc-23900,), and 211 
secondary antibody (1/200) was used under the same conditions. DAPI (Sigma D9542-212 
1MG) staining was performed overnight and after a washing step samples were 213 
visualized.   214 
 215 
Tumor pathology 216 
The human tissues were procured after obtaining the patient written consent and with 217 
the approval of the ethics committees of Hospital Universitario 12 de Octubre. 218 
Hematoxylin-Eosyn (H&E) staining was performed on 5 μm thick sections from paraffin-219 
embedded tumors. Pseudopalisades areas were selected and the nuclear shape in the 220 
rear end (close to the necrotic core) or at the front was calculated as previously 221 
described. Twenty nuclei were analyzed in each region. Three different samples were 222 
analyzed. All methods were carried out in accordance with the approved guidelines. 223 
 224 
Mathematical modeling 225 
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This model is based on our previous models10,16 where oxygen coming from straight 226 
vessels was the driving force that triggered the normoxic and hypoxic phenotypic 227 
changes. To these two dominant phenotypes, based on the go or grow dichotomy17, we 228 
have incorporated a third phenotype accounting for hypoxic cells that arrive to 229 
normoxic areas and switch to a more proliferative phenotype. Also, in addition to the 230 
diffusive random motion, we have comprised a directional transport term driving the 231 
cell’s motion towards better oxygenated regions for hypoxic cells that was not present 232 
in Refs10,16. 233 
 234 
The mathematical model consists of a set of partial differential equations modelling the 235 
interplay of three cellular cancer cell phenotypes, the oxygen distribution and necrosis: 236 
Major assumptions of the Mathematical Model:  237 
1. Hybrid model between go or grow and go and grow models. 238 
2. Classical logistic space-limited growth for the tumor cell populations. 239 
3. Hypoxic phenotype is more migratory than any other cell phenotype   240 
4. Oxygen acts as a chemoattractant for hypoxic cells. 241 
5. Malignant cells have the highest proliferation  242 
6. Homogenous and isotropic oxygen diffusion in the chamber  243 
7. Oxygen flows from channels to balance the different oxygen pressures.  244 
8. Malignant cells consume more oxygen than any other cell phenotype  245 
 246 
Statistical analysis 247 
Data were analyzed using SPSS software, and statistical significance was set at p < 248 
0.05. Results are presented as mean ± standard error. The normal distribution was 249 
tested by the Kolmogorov-Smirnov test. For parametric comparison, one way ANOVA 250 
with Bonferroni post hoc tests was performed. For nonparametric comparisons, a 251 
Kruskal-Wallis test was performed followed by the U-test of Mann-Whitney. 252 
N-O-D-15-00671R3 
 
11 
 
 253 
RESULTS 254 
 255 
GBM cells are viable in 3-dimensional microchamber culture 256 
The fabricated microdevice possesses a central microchamber to locate the cells 257 
embedded within a hydrogel18-20, mimicking the ECM and allowing migration in three 258 
dimensions. On both sides of the microchamber, lateral microchannels are filled with 259 
culture medium, allowing nutrient and oxygen diffusion throughout the microchamber, 260 
mimicking the function of brain blood vessels.  261 
 262 
We first examined microdevice biocompatibility with GBM cells to ensure the material 263 
does not affect cell viability. After 7 days in culture, we evaluated U-251 cell viability 264 
within microdevices compared to culture dish controls using CAM and propidium iodide 265 
(PI). Results showed that cell viability within microdevices was very high (>95%) and 266 
more importantly it was similar to culture controls at the same timepoint, validating the 267 
use of this microdevice for three dimensional U-251 cell culture (Fig. 1E, F). 268 
 269 
Flow profile 270 
Culture medium supplemented with 1% spheres suspension was injected through the 271 
lateral microchannel in obstructed conditions to study the flow profile. Fluorescent time-272 
lapse images demonstrated that under obstructed conditions the flow profile was not 273 
penetrating into the hydrogel (Supporting Fig. 1A-C), but it was completely parallel to 274 
the central microchamber. When an interstitial flow through the central microchamber 275 
was externally imposed, the fluorescent spheres invaded the hydrogel in few minutes 276 
(Supporting Fig. 1D-F). Therefore, under obstructed conditions the fluid flow is not 277 
mechanically affecting the hydrogel or the embedded cells.  278 
 279 
GBM cells migrate under obstructed conditions 280 
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By controlling medium flow through the lateral microchannels, we can mimic the GBM-281 
associated thrombotic pathophysiological conditions. Under unrestricted conditions, cell 282 
distribution within the microchamber was constant throughout the experiment (nine 283 
days of culture, Fig. 2A-C). Under obstructed conditions, cell viability continued to be 284 
very high (>95%) and we also observed a strong migratory process. After three days of 285 
thrombotic conditions, cell migration was barely apparent and only small cell 286 
aggregates near the perfused microchannel were visible (Fig. 2D). After six days, 287 
migration evolved to the formation of a well-defined front, resembling the in vivo 288 
observed pseudopalisades (Fig. 2E). Finally, after nine days this front moved closer to 289 
and invaded the perfused microchannel (Fig. 2F). In order to perform a more 290 
quantitative and precise analysis, we analyzed the fluorescence intensity across the 291 
microchamber. This analysis of cell distribution confirmed that under unrestricted 292 
conditions there was no change during the time course (Fig. 2G). On the other hand, 293 
after three days under obstructed conditions this distribution showed a moderate 294 
increase nearby the perfused lateral microchannel compared to the unrestricted 295 
conditions, showing an emerging migratory response (Fig. 2H). After six days, this 296 
response increased to a well-defined peak, indicating cells concentrating in this region, 297 
creating the characteristic pseudopalisade front and abandoning the occluded rear 298 
region. After nine days, the intensity of the pseudopalisade front reached a maximum 299 
and was displaced as cells reached the perfused lateral microchannel. This is the first 300 
experimental evidence showing the creation of a pseudopalisade front by a migratory 301 
wave of GBM cells moving from obstructed to perfused conditions. In order to expand 302 
this study using another GBM cell line, C-6 cells were cultured in the microdevice under 303 
similar conditions. After 3 days under obstructed conditions, C-6 cells showed an 304 
invasion process towards the perfused lateral microchannel (Supporting Fig. 2). 305 
Interestingly, C-6 cells exhibited a faster invasion than U-251 MG. Furthermore, a 306 
population of dead C-6 cells appeared concentrated nearby the obstructed lateral 307 
microchannel. Thereby, C-6 cells seemed to have a faster metabolism compared with 308 
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U-251 MG, which led to an accelerated invasion. Longer invasion times using C-6 cells 309 
were not analyzed due to a significant hydrogel contraction caused by these cells. 310 
 311 
Cell morphology analysis during pseudopalisade formation 312 
Our results suggested that pseudopalisading structures can be created by a migratory 313 
response lead by cells located at the rear of the migratory front, near the non-perfused 314 
microchannel. We next investigated the morphologic changes in GBM cells during the 315 
formation of pseudopalisades. As expected, after 5 days of culture cells under 316 
unrestricted conditions appeared identical on either side of the microchamber (Fig. 3A). 317 
Conversely, five days after the induction of obstructed conditions cell morphology 318 
clearly shifted in the cell population closest to the obstructed channel (Fig. 3B). In the 319 
rear, cells greatly increased in aspect ratio (5.3 ± 2.3) and became highly elongated 320 
with very large protrusions, whereas in the front cells were mainly rounded with aspect 321 
ratio close to one (1.2 ± 0.2) (p-value < 0.001) (Fig. 3C). We analyzed cell directionality 322 
near the obstructed channel and found a bias towards the medium flow (Fig. 3D). Cell 323 
directionality in those regions with lower aspect ratio (≈1) was not analyzed, since this 324 
parameter is irrelevant in rounded cells. Interestingly we observed the same cellular 325 
pattern in the pseudopalisades detected in human GBM samples, with a significant 326 
change in the nucleus aspect ratio (2.1 ± 0.5) in the rear end (close to the necrotic 327 
core) compared to the front (1.3 ± 0.2) (Fig. 3E and F). 328 
 329 
Characterization of pseudopalisade formation 330 
A recent hypothesis about GBM suggests that when migrating cells forming the 331 
pseudopalisade reach a new nutrient rich microenvironment (i.e. in the vicinity of a 332 
perfused blood vessel) their metabolism changes back to a more proliferative and less 333 
migratory state. To test this hypothesis within our system, we analyzed cell proliferation 334 
under the different stages of pseudopalisade formation by Ki-67 immunofluorescence. 335 
After 5 days under obstructed conditions, we observed no Ki-67 positive cells (Fig. 4A). 336 
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On the other hand, when the pseudopalisade was completely formed after 9 days 337 
under obstructed conditions, positive cells were observed (Fig. 4B). More interestingly, 338 
those proliferative cells appeared only in the vicinities of the perfused microchannel 339 
where nutrient concentrations are expected to be highest. Under unrestricted 340 
conditions we did not observed positive cells either after 5 or after 9 days (Fig. 4C and 341 
D). Central microchamber was vertically divided in three regions and the number of 342 
proliferating cell was determined in each one (Fig 4E). The analysis demonstrated most 343 
of the proliferating cells were located on the region closest to the perfused lateral 344 
microchannel, only a small proportion appeared in the central region, and no 345 
proliferating cells were observed in the further region.   346 
To determine if a glucose gradient was generated during long-term experiments, we 347 
analyzed the diffusion profile of the fluorescent glucose analog 2-deoxy-2-[(7-nitro-348 
2,1,3-benzoxadiazol-4-yl)amino]-D-glucose (NBDG) across the microchamber in the 349 
absence or presence of cells (Supporting Fig. 3) during 2 hours post-NBDG injection. 350 
We found little difference in cellular glucose uptake across the microchamber and cells 351 
were able to uptake the NBDG. The NBDG diffusion profile without cells (green line) 352 
was very similar to the NBDG with cells curve (red line). (Note: the dark areas 353 
observed in the assay containing cells are due to light scattering from cells out of the 354 
focal plane. Supporting Fig. 4). After removing the NBDG, cell remained labelled in 355 
green, showing their ability to incorporate the glucose analog (Supporting Fig. 5). This 356 
indicates that during long-term experiments GBM cells are not exposed to a significant 357 
glucose gradient and further suggests that pseudopallisading formation is driven by 358 
factors other than glucose scarcity. 359 
We next investigated the oxygen profile across the microchamber during experiments 360 
using Image-it hypoxia reagent which becomes fluorescent as oxygen tension 361 
decreases. Two different sets of experiments were performed, both carried out for 5 362 
days: Under unrestricted conditions medium was pipetted only once a day through both 363 
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lateral microchannels. Since both lateral microchannels remained open, the oxygen 364 
consumption was symmetric; thereby, a homogeneous hypoxia along the 365 
microchamber was generated (Fig 5A and Supporting Fig 6A).  366 
On the other hand, under obstructed conditions the medium flow through the right 367 
lateral microchannel guaranteed that oxygen and nutrients in the perfused lateral 368 
microchannel were continuously refreshed; whereas the opposed lateral microchannel 369 
remained blocked. Thereby, those cells located nearby to the perfused microchannel 370 
showed very low hypoxia-induced fluorescence intensity, suggesting a normoxic 371 
microenvironment; whereas those cells located nearby the blocked microchannel 372 
showed the highest hypoxia-induced fluorescence intensity (Fig 5B, C and Supporting 373 
Fig 5B). 374 
These results suggested that gradient conditions were needed to induce the directional 375 
migratory process, since under “unrestricted conditions” no directional migration was 376 
observed even when a homogenous hypoxia was observed.  377 
 378 
Correlation of computer simulations with experimental data 379 
Since the migratory response of the GBM cells is non-linear and not entirely intuitive, 380 
we investigated the correlation of our experimental data with simulated computer 381 
models. Under unrestricted conditions, the number of cells and their distribution along 382 
the chamber vary only slightly due to the very slow proliferation rates we observe (Fig 383 
6A). In our computer simulations, all cells have a normoxic phenotype after 9 days. 384 
When the nutrient flow along the left channel was disrupted, cellularity remained 385 
spatially homogeneous for 3 days while the nutrient level becomes exhausted, after 386 
which cells slowly change their phenotypes. However, our numerical simulations reveal 387 
the formation of a pseudopalisade structure moving towards the active channel after 6 388 
days and a dramatic increase in cell density around the flow channel at day 9 (Fig. 6B), 389 
which is strongly in agreement with our experiments. Fig. 8C shows the mathematical 390 
model scheme used in the computational simulations. We have performed an 391 
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extensive parameter value scans and we are forced to conclude that the dynamic 392 
behavior observed in our experimental model cannot be reproduced within the 393 
framework of the previously published two-phenotype computational model10,16 which 394 
assumes that tumor cells revert to their original normoxic phenotypes when reaching 395 
areas of higher oxygenation. Instead, the incorporation of a third highly proliferative 396 
phenotype after the wave of migration is essential to reproduce the evolution of our 397 
observed cell density profiles during pseudopalisade generation. Our analysis suggests 398 
the existence of a highly proliferative GBM cell state triggered by transient waves of 399 
metabolic deprivation and migration (Figure 6C). 400 
 401 
DISCUSSION 402 
 403 
Nutrient and oxygen depletion due to blood vessel obstruction events play an important 404 
role on the accelerated spreading of GBM cells across the brain. In this work, we 405 
provide a robust and novel methodology to mimic the GBM-associated blood vessel 406 
obstruction in vitro. Using our developed microdevice, we were able to culture GBM 407 
cells under induced obstructed conditions and for the first time we can demonstrate the 408 
formation of a pseudopalisade-like front through several sequential steps. In an initial 409 
stage, during the first days under obstructed conditions, there is little morphologic 410 
change in the GBM cells as remaining oxygen and nutrients are consumed. In a 411 
second stage, nutrient starvation leads to an intense migratory response in those cells 412 
located in the starved region, i.e. the pseudopalisade rear. This migratory response 413 
creates the observed pseudopalisading structures after six days in culture. Finally, in a 414 
third stage, cells of this pseudopalisade front reach the nutrient source (invading the 415 
perfused lateral microchannel) and undergo rapid proliferation. This behavior models 416 
GBM pseudopalisade progression observed in patients and enables the study of this 417 
phenomenon in vitro. The pseudopalisading hypothesis has been suggested to explain 418 
the poor improvement on mean survival time achieved by conventional anti-tumorigenic 419 
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treatments21. Accordingly, the approved chemotherapy treatment for GBM, based on 420 
concomitant doses of the alkylating chemotherapy agent temozolomide combined with 421 
radiotherapy, only improves mean survival time by a few months compared with 422 
radiotherapy only1,21. Since most such treatments are focused on killing proliferative 423 
cells they do not target those non-proliferative migratory cells of pseudopalisades.  424 
Unfortunately, once these cells reach nutrient rich regions they can again become 425 
proliferative.  426 
 427 
Many recent reports show that cell migration palys a critical role on GBM invasion and 428 
spreading, and correlates with patient prognosis22-24.  In this context, new drugs are 429 
being developed to block GBM cells migration25. Thus, different animal and in vitro 430 
studies show that treatment with specific migration inhibitors can achieve a significantly 431 
mean survival time improvement26,27. It has been shown GBM cells invade by a 432 
mesenchymal migration mode28-30 based on integrins and matrix degrading enzymes 433 
like membrane type matrix metalloproteinase-1 (MT-MMP-1) and MMP-2 31,32. These 434 
proteins normally are overexpressed in GBM33. More interestingly, recent reports have 435 
shown hypoxia, through HIF-1α, induce an epithelial-mesenchymal transition (EMT) in 436 
GBM cell lines, enhancing cell invasiveness34. In our model, cells showed this expected 437 
mesenchymal-like GBM migration mode, including the characteristic emission of 438 
invadopodia and very large aspect ratio35. Our directionality distribution showed that 439 
rear cells were preferentially orientated towards the perfused lateral microchannel (the 440 
oxygen and nutrient source), forming an angle of 90o with medium flow and aligning in 441 
the direction of travel during pseudopalisade formation.  442 
 443 
Our oxygen profile measurements reveal that under obstructed conditions cell 444 
metabolism creates an oxygen gradient across the microchamber, resembling the 445 
hypoxic areas observed in in-vivo pseudopalisades. Our mathematical model suggests 446 
the development of a more malignant phenotype after these cycles of hypoxia, 447 
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migration, and re-oxygenation. This phenotype is highly proliferative and oxygen 448 
dependent. Our mathematical simulations support the hypothesis of pseudopalisade 449 
formation after a vessel occlusion event and correlate very well with microfluidic device 450 
experiments, in which we saw an increase in the cell proliferation when the cells where 451 
exposed to obstructed conditions. Our results suggest that both the enhanced 452 
infiltration and the malignant phenotype arising after hypoxic cells reach better 453 
oxygenated areas may be relevant tumor driving forces originated by microscopic 454 
hypoxic events. Therefore, this mathematical model is able to recapitulate the 455 
pseudopalisade formation as a hypoxia-driven phenomenon, convincingly reproducing 456 
the observed results within the microdevice and the observed pseudopalisades in vivo. 457 
 458 
Our interdisciplinary approach now allows direct observation of GBM invasion and 459 
pseudopalisade formation under controlled conditions. Furthermore, the mathematical 460 
modeling suggests a sequence of cell states which include alternating phases of 461 
hypoxia, invasiveness, and proliferation. These methodologies enable us to see 462 
processes once only found in vivo, shed light on the states and life cycle of GBM, and 463 
could enable more biologically accurate drug screening methods focused on GBM 464 
invasion. 465 
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 595 
 596 
Fig 1. Experimental set-up. A) Scheme of pseudopalisade formation. Under 597 
obstructed conditions, nutrient scarcity triggers a migratory response in those cells 598 
located in the obstructed blood vessel vicinity (I) towards enriched regions (II). B) 599 
Experimental scheme within the microdevice, mimicking the obstructed conditions and 600 
the starved (I) and enriched (II) region. C) Fabricated microdevice and packaging tool. 601 
D) Microfluidic system. E) U-251 cell viability within the microdevice after 9 days, live 602 
cells (labelled with Calcein 1 µg/ml) are shown in green whereas dead cells are in red 603 
(labelled with Propidium iodide 4 µg/ml). Microdevice posts (50x100 µm) are delimited 604 
in white dashed line. Cells were cultured at 4 million cells/ml within a 1.5 mg/ml 605 
collagen hydrogel. Viable cells are shown in green, whereas dead ones are in red. F) 606 
Cell viability comparison between hydrogels on Petri dishes (red) and within the 607 
microdevice (blue). Cell viability is expressed as the percentage of live cells. Scale bar 608 
is 200 µm. 609 
 610 
Fig 2. Pseudopalisade formation under obstructed conditions. U-251 at 4 million 611 
cells/ml in collagen hydrogel at 1.5 mg/ml were culture within microdevices. Under 612 
unrestricted conditions medium was refreshed once a day and cell viability was 613 
evaluated at three (A), six (B) and nine (C) days using Calcein (green) and propidium 614 
iodide (red). To mimic obstructed conditions, medium flow was enabled only through 615 
right microchannel and cell viability was assessed at three (D), six (E) and nine (F) 616 
days. Microdevice posts (50x100 µm) are delimited in white dashed line. Graphs show 617 
the fluorescence intensity across the microchamber orthogonal view at three (G), six 618 
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(H) and nine days (I) in obstructed as unrestricted conditions. Post position in the 619 
graphs is delimited by gray dashed line. Scale bar is 200 µm. 620 
Fig 3. Cell shape during Pseudopalisade formation. Confocal images of the 621 
microchamber after five days in culture under unrestricted (A) or obstructed conditions 622 
were taken (B). C) Cell shape at the pseudopalisade rear and front was analyzed and 623 
compared with the same region under unrestricted conditions, *** denotes a statistical 624 
difference (p-value 1.4x10-32). D) Directionality at the pseudopalisade rear under 625 
obstructed conditions. E) H&E staining of a paraffin-embedded GBM sample. F) 626 
Nucleus aspect ratio in the pseudopalisade rear and front in patient samples, *** 627 
denotes a statistical difference (p-value 3.7x10-8). Scale bar is 200 µm. 628 
Fig 4. Proliferation during pseudopalisade formation. Ki-67 immunofluorescence 629 
was performed within the microdevices during the different steps of the pseudopalisade 630 
formation. A-B) Under obstructed conditions, ki-67 positive cells were observed only 631 
after 9 days, when the pseudopalisade was completely formed. C-D) Under 632 
unrestricted conditions no positive cells were observed at 5 or 9 days. Scale bar is 200 633 
µm. 634 
Fig 5. Oxygen profile. Oxygen profile was detected after 5 days in culture using 635 
Image-it Hypoxia reagent and images are shown as heat-map hypoxia-induced 636 
fluorescence intensity. Hypoxia-induced fluorescence intensity across the 637 
microchamber revealed oxygen concentration was constant under unrestricted 638 
conditions (A), whereas under obstructed conditions an oxygen gradient was 639 
established (B). The graph shows the hypoxia-induced fluorescence intensity profile 640 
across the microchamber (C). Scale bar is 200 µm. 641 
Fig 6. Computer simulations versus experimental data of the cell evolution 642 
profiles.  Simulations of tumor cell density evolution and experimental data of 643 
fluorescence intensity within the chamber under unrestricted conditions (A) and under 644 
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obstructed conditions (B). Left Y axis denotes fluorescence intensity from experiments 645 
at day 3, 6 and 9, curves red blue and black respectively. Right Y axis denotes cell 646 
density from simulations at day 3, 6 and 9, red spots, blue cross and black circles 647 
respectively. Post position in the graphs is delimited by gray dashed line. C) Graphical 648 
depiction of the mathematical model scheme based on previous models [10, 13] and 649 
including three cancer cell phenotypes, the oxygenation and the necrosis (C). 650 
651 
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Fig 1. 652 
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Fig 2. 655 
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Fig 3. 658 
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Fig 4. 661 
 662 
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Fig 5. 666 
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Fig 6. 672 
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Supporting Fig 1. Flow characterization. Green-fluorescent spheres were dissolved 675 
in the culture medium to study the flow profile during long-term experiments under 676 
obstructed conditions. A-C) Fluorescent time-lapse images during obstructed 677 
conditions showed no sphere penetration in the hydrogel. D-F) Interstitial flow through 678 
the hydrogel was created opening one of the inlets of the “sealed” lateral microchannel 679 
and closing one of the “perfused” one to illustrate the fluorescent spheres penetration. 680 
Scale bar is 200 µm. 681 
Supporting Fig 2. C6 cells cultured within the microdevices. 4 million C6 GBM 682 
cells/ml were embedded in a 1.2 mg/ml collagen hydrogel and confined in the central 683 
microchamber. Microdevices were cultured under unrestricted conditions (A) or 684 
obstructed conditions (B). After 3 days, cell viability was analyzed with CAM/PI 685 
staining; showing viable cells in green and dead ones in red. Graphs show the 686 
viable/dead cell fluorescence intensity distribution along the delimited region (yellow 687 
rectangle in the images). Pillar position is shown in dashed line. Scale bar is 200 µm.   688 
Supporting Fig 3. Glucose profile. Glucose-free culture medium supplemented with 689 
200 µm NBDG was perfused through the lateral microchannel. Cells were fluorescently 690 
labelled in red and the NBDG diffusion profile was studied in the presence (red line) 691 
and absence (green line) of cells after 10 (A), 60 (B) and 120 (C) min. Scale bar is 200 692 
µm. 693 
Supporting Fig 4. NBDG diffusion profile. During NBDG diffusion, dark spots were 694 
observed within the hydrogel when Dil-labelled cells were present. Those spots 695 
corresponded to cells out of focus that caused green-light scattering. Scale bar is 200 696 
µm. 697 
Supporting Fig 5. NBDG uptake. After perfusing NBDG through the right 698 
microchannel, growth medium was perfused through the system to remove the NBDG. 699 
Dil-labelled cells remained fluorescent in the hydrogel, and now green fluorescent was 700 
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observed within the cells, demonstrating their ability to incorporate the NBDG. Scale 701 
bar is 200 µm. 702 
Supporting Fig 6. Oxygen profile. Oxygen profile was detected after 5 days in culture 703 
using Image-it Hypoxia reagent. Hypoxia-induced fluorescence intensity across the 704 
microchamber revealed oxygen concentration was constant under unrestricted 705 
conditions (A), whereas under obstructed conditions an oxygen gradient was 706 
established (B). Scale bar is 200 µm. 707 
708 
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Supporting Fig 1. 709 
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Supporting Fig 2. 712 
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Supporting Fig 3. 715 
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Supporting Fig 4. 719 
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Supporting Fig 6. 726 
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